Unlikely to cause harm — often a labeling or packaging issue.
CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.
| Brand name | LISINOPRIL |
| Generic name | LISINOPRIL |
| Active ingredient(s) | LISINOPRIL |
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, MD 21202, United States; |
| NDC | 68180-516-02 |
| Full product label | Lisinopril Tablets USP, 30 mg, packaged in a) 500-count bottles (NDC 68180-516-02) and b) 100-count bottles (NDC 68180-516-01); Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, MD 21202, United States; Manufactured by: Lupin Limited, Pithampur (M.P.) 454 775, INDIA. |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | All product distributed domestically in the US. No recalled product was distributed to U.S. Government Agency consignees directly by Lupin. No recalled product was distributed to any foreign consignees by Lupin. |
| Quantity | 20,556 bottles |
| Recall initiated | 2016-04-06 |
| Report date | 2016-09-28 |
| Recall completed | 2017-08-07 |
| Recall number | D-1502-2016 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗